Cutting Edge Science
One of the most unique aspects of the IMSMP is the seamless association with a state-of-the-art research facility. The Tisch MS Research Center of New York is an adjoining research center, currently investigating many different aspects of MS treatment and neuro-immunology. The stem cell research being performed at the Tisch MS Research is particularly intriguing. Such close proximity to cutting edge scientific breakthroughs provides hope to patients that we will continue to improve our MS treatments on the way to someday finding a cure.
Current Clinical Trials at the IMSMP
Clinical trials help doctors and scientists test the safety and effectiveness of new or investigational medications. Many of the medications used at the IMSMP were tested in clinical trials to demonstrate their effectiveness in treating MS. Clinical trials have both potential risks and benefits for people who participate in them. Ineffective medication and possible side effects are potential risks, while receiving treatment otherwise unavailable and helping others with MS by contributing to medical research are among the potential benefits.
Below are some of the current clinical trials being conducted at the IMSMP.
This study examines the incidence of adverse events and JC virus antibody formation in patients treated with Natalizumab (Tysabri). The goal of this project is to stratify patients into groups with a higher and lower risk of developing PML. Of available samples to date, no one who tested negative for the JC virus antibody has contracted Natalizumab-associated PML.
Accelerated Cure Project
The IMSMP/Tisch MS Research is also involved in the Accelerated Cure Project. This is a large project aims that compiles epidemiological data on patients and families with MS. The study entails answering questionnaires, reviewing your medical chart and a blood sample.
We are examining the association between cognitive dysfunction and the expression of certain biomarkers in the cerebrospinal fluid (CSF) and brain of MS patients.
We continue to further investigate the novel administration of this medication for MS, the protocol of which was created by Dr. Sadiq many years ago. Currently, we are systematically following patients to evaluate efficacy and safety, evaluating CSF biomarkers of treated patients, and reporting on the long-term safety of our patients who have continued on this treatment for over 3 years.
Skin Biopsy Study
This study will look to see if microscopic changes in the skin can help us differentiate atypical from typical cases of MS.
Acetyl-L-Carnitine Fatigue Study
This study hopes to determine if Acetyl-L-Carnitine, a natural supplement, is helpful at reducing fatigue and improving endurance.
This study is a long-term safety monitoring study of patients who have recieved Mitoxantrone for the treatment of MS.
For more information on any new clinical research please call Deirdre Dulak (646) 557-3860.